Merck Sharp & Dohme LLC — Sponsor Intelligence | 293 EU Trials

Filter these 293 trials by condition, phase, country and more.

Open in Search →

293 Registered trials

92 Recruiting

189 Completed trials

25 Countries active

165 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 117 Phase II/III: 13 Phase II: 62 Phase I/II: 33 Phase III/IV: 5 Phase I: 24 Phase I (Other): 36 Phase I (FiH): 3

Oversight events:

4 serious breaches 72 temporary halts 6 urgent safety measures 9 unexpected events 9 corrective measures across 37 trials

View oversight register →

100%

189 of 189 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer metastatic 8 Renal cell carcinoma 8 Non-small cell lung cancer 6 Non-alcoholic steatohepatitis 4 Respiratory syncytial virus infection 4 Non-small cell lung cancer stage IV 3 Pulmonary arterial hypertension 3 Rheumatoid arthritis 3 Bladder cancer 3 Hormone receptor positive HER2 negative breast cancer 3 Prostate cancer metastatic 3 Hormone receptor positive breast cancer 2

Top IMPs

PEMBROLIZUMAB 114 LENVATINIB 26 SACITUZUMAB TIRUMOTECAN 23 PEMBROLIZUMAB, VIBOSTOLIMAB 13 PEMBROLIZUMAB, FAVEZELIMAB 12 BELZUTIFAN 11 OLAPARIB 11 MK-4830 10 MRNA-4157 9 IFINATAMAB DERUXTECAN 8 PATRITUMAB DERUXTECAN 8 PEMBROLIZUMAB, QUAVONLIMAB 8

All trials — page 10

293 total

A clinical study of MK-1403 in healthy men Ended

2023-504695-23-00 Phase I 1 country MK-1403
A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line met… Ended

2023-506385-30-00 Phase I/II 4 countries
A clinical study of the V116 vaccine for adults who have an increased risk for invasive pneumococcal disease Ended

2022-502791-22-01 Phase III 1 country PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F CONJUGATED TO CRM197, PNEUMOCOCCAL POLY…
Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML Ended

2023-503580-42-00 Phase I (Other) 1 country
MK-7602 Multiple Ascending Dose Study in Healthy Participants Ended

2023-503738-36-00 Phase I (Other) 1 country MK-7602
A Single-Ascending-Dose Study of MK-4318 in Healthy Participants Ended

2023-503360-16-00 Phase I 1 country
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants Ended

2022-502926-42-00 Phase I 1 country
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination … Ended

2023-504855-28-00 Phase I 1 country
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Particip… Ended

2023-504017-79-00 Phase II 2 countries MK-1942
Safety and Immunogenicity of V116 in Adults 50 Years of Age or Older Ended

2022-503144-40-00 Phase III 2 countries PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F CONJUGATED TO CRM197, PNEUMOCOCCAL POLY…
A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended

2022-500350-42-01 Phase II/III 7 countries
MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended

2023-503615-14-00 Phase II 7 countries PEMBROLIZUMAB, FAVEZELIMAB
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian… Ended

2023-505005-16-00 Phase II 4 countries MK-4830; PEMBROLIZUMAB
A Study of MK-1088 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors Ended

2022-502288-40-00 Phase II 1 country MK-1088; PEMBROLIZUMAB
A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with… Ended

2022-502752-31-00 Phase III/IV 11 countries DURVALUMAB; ETOPOSIDE; PEMBROLIZUMAB, VIBOSTOLIMAB; PEMETREXED
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir… Ended

2023-506074-12-00 Phase III 5 countries PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; PEMBROLIZUMAB, VIBOSTOLIMAB; PEMETREXED
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes… Ended

2022-501243-33-00 Phase II 9 countries ZILOVERTAMAB VEDOTIN
Clinical trial of MK-4280A for colorectal cancer that has spread after previous treatment Ended

2024-511043-25-00 Phase III 4 countries PEMBROLIZUMAB, FAVEZELIMAB
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe … Ended

2022-500752-39-00 Phase III 9 countries CLESROVIMAB; PALIVIZUMAB; SODIUM CHLORIDE
MK-2060 Global Study in Patients with End Stage Renal Disease Receiving Hemodialysis Ended

2024-511055-17-00 Phase II 8 countries MK-2060
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended

2022-501615-14-00 Phase II 4 countries PEMBROLIZUMAB
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Phase III 12 countries VERICIGUAT
A Drug Absorption Study of MK-3475A in Participants with Solid Tumors Ended

2023-505340-19-00 Phase I (Other) 2 countries
7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended

2023-505284-36-00 Phase II 6 countries LENVATINIB; PEMBROLIZUMAB; PEMBROLIZUMAB, VIBOSTOLIMAB

Showing 217–240 of 293 trials

← All sponsors A–Z